EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%

by Paul Zarogoulidis, Panos Chinelis, Christofors Efthymiou, Anastasia Athanasiadou, Vasilis Mpikos, George Papatsibas, Vasilis Papadopoulos, Elena Maragouli, Haidong Huang, Georgia Trakada, Anastasios Kallianos, Lemonia Veletza, Wolfgang Hohenforst-Schmidt
Published 2017-01-01